• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 71963-77-4 Price $40 / 20mg
    Catalog No.CFN99184Purity>=98%
    Molecular Weight298.38Type of CompoundSesquiterpenoids
    FormulaC16H26O5Physical DescriptionWhite powder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • University of Indonesia (Indonesia)
  • National Research Council of Can... (Canada)
  • The Australian National University (Australia)
  • University of Canterbury (New Zealand)
  • Guangzhou Institutes of Biomedic... (China)
  • University of Perugia (Italy)
  • University of Madras (India)
  • University of the Basque Country (Spain)
  • Molecular Biology Institute of B... (Spain)
  • Ateneo de Manila University (Philippines)
  • Biotech R&D Institute (USA)
  • More...
  • Package
    Featured Products

    Catalog No: CFN90232
    CAS No: 495-31-8
    Price: $138/20mg
    Ginsenoside Compound K

    Catalog No: CFN99756
    CAS No: 39262-14-1
    Price: $100/20mg
    3,6'-Disinapoyl sucrose

    Catalog No: CFN90578
    CAS No: 139891-98-8
    Price: $138/20mg
    Ginsenoside Rg6

    Catalog No: CFN90565
    CAS No: 147419-93-0
    Price: $488/10mg
    Ganoderiol F

    Catalog No: CFN99244
    CAS No: 114567-47-4
    Price: $398/5mg
    Biological Activity
    Description: Artemether is a novel sonosensitizer,which has neurotoxicity, anti-schistosomiasis, anticancer and antitumor activities. It is an antimalarial for the treatment of resistant strains of falciparum malaria.
    Targets: Antifection
    In vivo:
    Chem Commun (Camb). 2015 Mar 3;51(22):4681-4.
    Potential sonodynamic anticancer activities of artemether and liposome-encapsulated artemether.[Pubmed: 25691357]
    The potential application of Artemether as a novel sonosensitizer for sonodynamic therapy (SDT) was explored and illustrated for the first time. In addition, liposome-encapsulated Artemether exhibited significantly enhanced sonodynamic anticancer activity. Our findings indicated that artemisinin derivatives may serve as a new kind of sonosensitizer for SDT.
    Acta Trop. 2002 May;82(2):175-81.
    Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia.[Pubmed: 12020890]
    Two decades ago, a group of Chinese scientists discovered the antischistosomal properties of Artemether, a derivative of the antimalarial drug artemisinin. However, it was only recently that the importance of this finding was recognized internationally, following a collaborative effort between Chinese, European and African scientists, who investigated the effects of Artemether against the major human schistosome species.
    Laboratory studies revealed that Artemether exhibits the highest activity against juvenile stages of the parasites, while adult worms are significantly less susceptible. There was no indication of neurotoxicity following repeated high doses of Artemether given fortnightly for up to 5 months. Randomized controlled clinical trials confirmed that Artemether, orally administered at a dose of 6 mg/kg once every 2-3 weeks, results in no drug-related adverse effects, and significantly reduces the incidence and intensity of schistosome infections. The risk that these treatment regimens might select for resistance, particularly for resistant-plasmodia, appears to be low. Combined treatment with Artemether and praziquantel, given to animals harbouring juvenile and adult schistosome worms, resulted in significantly higher worm burden reductions than each drug administered singly.
    In conclusion, Artemether-integrated with other control strategies-has considerable potential for reducing the current burden of schistosomiasis in different epidemiological settings.
    Artemether Description
    Source: The herbs of Artemisia annua L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN92125
    CAS No: 75969-83-4
    Price: $413/5mg

    Catalog No: CFN92172
    CAS No: 22688-79-5
    Price: $318/10mg
    Epimedin B1

    Catalog No: CFN95017
    CAS No: 133137-58-3
    Price: $268/5mg
    Dehydrotrametenolic acid

    Catalog No: CFN90577
    CAS No: 29220-16-4
    Price: $268/20mg
    Magnolignan C

    Catalog No: CFN96189
    CAS No: 93697-42-8
    Price: $413/5mg

    Catalog No: CFN93257
    CAS No: 2608-21-1
    Price: $368/5mg
    Lappaol A

    Catalog No: CFN95067
    CAS No: 62333-08-8
    Price: $333/10mg

    Catalog No: CFN96588
    CAS No: 50816-24-5
    Price: $268/20mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.3514 mL 16.7572 mL 33.5143 mL 67.0286 mL 83.7858 mL
    5 mM 0.6703 mL 3.3514 mL 6.7029 mL 13.4057 mL 16.7572 mL
    10 mM 0.3351 mL 1.6757 mL 3.3514 mL 6.7029 mL 8.3786 mL
    50 mM 0.067 mL 0.3351 mL 0.6703 mL 1.3406 mL 1.6757 mL
    100 mM 0.0335 mL 0.1676 mL 0.3351 mL 0.6703 mL 0.8379 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Animal Research:
    Antimicrob Agents Chemother. 2014 Oct;58(10):5658-65.
    Enhanced antimalarial activity by a novel artemether-lumefantrine lipid emulsion for parenteral administration.[Pubmed: 24982079]
    Artemether and lumefantrine (also known as benflumetol) are difficult to formulate for parenteral administration because of their low aqueous solubility. Cremophor EL as an emulsion excipient has been shown to cause serious side effects.
    This study reports a method of preparation and the therapeutic efficacies of novel lipid emulsion (LE) delivery systems with Artemether, lumefantrine, or Artemether in combination with lumefantrine, for parenteral administration. Their physical and chemical stabilities were also evaluated. Furthermore, the in vivo antimalarial activities of the lipid emulsions developed were tested in Plasmodium berghei-infected mice. Artemether, lumefantrine, or Artemether in combination with lumefantrine was encapsulated in an oil phase, and the in vivo performance was assessed by comparison with artesunate for injection. It was found that the lumefantrine lipid emulsion (LUM-LE) and Artemether-lumefantrine lipid emulsion (ARM-LUM-LE-3) (1:6) began to decrease the parasitemia levels after only 3 days, and the parasitemia inhibition was 90% at doses of 0.32 and 0.27 mg/kg, respectively, with immediate antimalarial effects greater than those of the positive-control group and constant antimalarial effects over 30 days.
    LUM-LE and ARM-LUM-LE-3 demonstrated the best performance in terms of chemical and physical stabilities and antiplasmodial efficacy, with a mean particle size of 150 nm, and they have many favorable properties for parenteral administration, such as biocompatibility, physical stability, and ease of preparation.
    Am J Trop Med Hyg. 1994 Sep;51(3):251-9.
    Fatal neurotoxicity of arteether and artemether.[Pubmed: 7943542]
    Artemisinin (qinghaosu) and several derivatives have been developed and are in use as antimalarial drugs but scant information is available regarding animal or human toxicity. Following a eight-day, multiple-dose, pharmacokinetic study of arteether (AE) (10 mg/kg/day [n = 6] and 20 mg/kg/day [n = 6]) in dogs, all high-dose animals displayed a progressive syndrome of clinical neurologic defects with progressive cardiorespiratory collapse and death in five of six animals. Neurologic findings included gait disturbances, loss of spinal and pain response reflexes, and prominent loss of brain stem and eye reflexes. Animals had prolongation of QT interval corrected for rate (QTc) on electrocardiograms (ECGs) with bizarre ST-T segment changes. Prominent neuropathic lesions were noted to be primarily limited to the pons and medulla. Similar lesions with dose-related severity were noted in eight other dogs studied in a second study with intramuscular (IM) administration of AE in sesame oil during a 28-day, dose-ranging study using 5, 10, 15, and 20 mg/kg/day. Injury, graded by a pathologist blinded to the dose group, showed a dose-related, region-specific injury in all animals that was most pronounced in the pons. Further studies in Sprague-Dawley rats using IM administration of AE and Artemether (AM) at a dose of 12.5-50 mg/kg/day for 28 days confirmed the onset of a clinical neurologic syndrome with dose-related changes in body weight, activity, and seizure-like activity, stereotypic movement disorders, and ECG changes